{
    "organizations": [],
    "uuid": "d2e60faa14c197f134c7dab6c802fe893153e1c7",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-says-chmp-of-ema-recommende/brief-pfizer-says-chmp-of-ema-recommended-against-expanding-use-of-sutent-idUSASB0C79V",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Says CHMP Of EMA Recommended Against Expanding Use Of Sutent",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "  8 minutes ago BRIEF-Pfizer Says CHMP Of EMA Recommended Against Expanding Use Of Sutent Reuters Staff 1 Min Read Feb 23 (Reuters) - Pfizer Inc: * PFIZER ANNOUNCES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR SUTENTÂ® (SUNITINIB) IN ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA * PFIZER - CHMP OF EMA RECOMMENDED AGAINST EXPANDING USE OF SUTENT  ",
    "published": "2018-02-23T15:37:00.000+02:00",
    "crawled": "2018-02-23T15:54:12.039+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "ago",
        "say",
        "chmp",
        "ema",
        "recommended",
        "expanding",
        "use",
        "sutent",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "announces",
        "update",
        "european",
        "marketing",
        "authorization",
        "application",
        "sunitinib",
        "adult",
        "patient",
        "high",
        "risk",
        "recurrent",
        "renal",
        "cell",
        "carcinoma",
        "pfizer",
        "chmp",
        "ema",
        "recommended",
        "expanding",
        "use",
        "sutent"
    ]
}